Summit Therapeutics Plc Stock Performance
| SMMT Stock | USD 15.88 0.20 1.28% |
The entity has a beta of 2.39, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Summit Therapeutics will likely underperform. Summit Therapeutics PLC right now has a risk of 3.98%. Please validate Summit Therapeutics total risk alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Summit Therapeutics will be following its existing price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Summit Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable primary indicators, Summit Therapeutics is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
One Day Return 1.28 | Five Day Return 7.73 | Year To Date Return (9.36) | Ten Year Return 111.73 | All Time Return 55.84 |
Last Split Factor 1:1 | Last Split Date 2020-09-21 |
1 | Summit Therapeutics Valuation Check After Weak Q3 2025 Results and Insider Share Purchases | 12/03/2025 |
2 | UK car industry on track to meet 2025 EV sales target | 12/22/2025 |
3 | Will Ivonescimabs FDA Filing and GSK Combo Trial Redefine Summit Therapeutics Core Narrative | 01/23/2026 |
4 | Acquisition by Zanganeh Mahkam of 26680 shares of Summit Therapeutics at 18.74 subject to Rule 16b-3 | 01/26/2026 |
5 | Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 01/30/2026 |
6 | Summit Therapeutics Research-Driven Model In Nasdaq Index | 02/03/2026 |
7 | Electric car market goes into reverse amid pay-per-mile tax threat | 02/05/2026 |
8 | UK car market up but sees EV share fall in January | 02/06/2026 |
9 | Is Summit Therapeutics Inc. One of the Most Oversold NASDAQ Stocks to Invest In | 02/12/2026 |
10 | Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Operational Progress Call on February 23, 2026 | 02/17/2026 |
| Begin Period Cash Flow | 71.4 M | |
| Total Cashflows From Investing Activities | -205.3 M |
Summit Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,619 in Summit Therapeutics PLC on November 21, 2025 and sell it today you would lose (31.00) from holding Summit Therapeutics PLC or give up 1.91% of portfolio value over 90 days. Summit Therapeutics PLC is currently generating 0.0458% in daily expected returns and assumes 3.9785% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Summit, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Summit Therapeutics Target Price Odds to finish over Current Price
The tendency of Summit Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 15.88 | 90 days | 15.88 | about 79.24 |
Based on a normal probability distribution, the odds of Summit Therapeutics to move above the current price in 90 days from now is about 79.24 (This Summit Therapeutics PLC probability density function shows the probability of Summit Stock to fall within a particular range of prices over 90 days) .
Summit Therapeutics Price Density |
| Price |
Predictive Modules for Summit Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Summit Therapeutics PLC. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Summit Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Summit Therapeutics is not an exception. The market had few large corrections towards the Summit Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Summit Therapeutics PLC, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Summit Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.28 | |
β | Beta against Dow Jones | 2.39 | |
σ | Overall volatility | 1.35 | |
Ir | Information ratio | -0.06 |
Summit Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Summit Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Summit Therapeutics PLC can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Summit Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (221.31 M) with profit before overhead, payroll, taxes, and interest of 705 K. | |
| Summit Therapeutics PLC currently holds about 121.97 M in cash with (142.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.61. | |
| Summit Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 86.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Operational Progress Call on February 23, 2026 |
Summit Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Summit Stock often depends not only on the future outlook of the current and potential Summit Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Summit Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 718.5 M | |
| Cash And Short Term Investments | 412.3 M |
Summit Therapeutics Fundamentals Growth
Summit Stock prices reflect investors' perceptions of the future prospects and financial health of Summit Therapeutics, and Summit Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Summit Stock performance.
| Return On Equity | -2.92 | ||||
| Return On Asset | -1.53 | ||||
| Current Valuation | 11.44 B | ||||
| Shares Outstanding | 744.44 M | ||||
| Price To Earning | 2.85 X | ||||
| Price To Book | 60.71 X | ||||
| Price To Sales | 753.90 X | ||||
| Gross Profit | 705 K | ||||
| EBITDA | (212.85 M) | ||||
| Net Income | (221.31 M) | ||||
| Cash And Equivalents | 121.97 M | ||||
| Cash Per Share | 0.61 X | ||||
| Total Debt | 7.22 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 8.22 X | ||||
| Book Value Per Share | 0.26 X | ||||
| Cash Flow From Operations | (142.11 M) | ||||
| Earnings Per Share | (1.25) X | ||||
| Market Capitalization | 11.67 B | ||||
| Total Asset | 435.56 M | ||||
| Retained Earnings | (1.21 B) | ||||
| Working Capital | 382.02 M | ||||
| Current Asset | 20.86 M | ||||
| Current Liabilities | 3.21 M | ||||
About Summit Therapeutics Performance
Assessing Summit Therapeutics' fundamental ratios provides investors with valuable insights into Summit Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Summit Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.59) | (0.62) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (0.65) | (0.69) |
Things to note about Summit Therapeutics PLC performance evaluation
Checking the ongoing alerts about Summit Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Summit Therapeutics PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Summit Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (221.31 M) with profit before overhead, payroll, taxes, and interest of 705 K. | |
| Summit Therapeutics PLC currently holds about 121.97 M in cash with (142.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.61. | |
| Summit Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 86.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Operational Progress Call on February 23, 2026 |
- Analyzing Summit Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Summit Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Summit Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Summit Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Summit Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Summit Therapeutics' stock. These opinions can provide insight into Summit Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.